Feedback (FDBK)

Sector:

Health Care

Index:

FTSE AIM All-Share

100.00p
   
  • Change Today:
    -2.50p
  • 52 Week High: 140.00
  • 52 Week Low: 58.00
  • Currency: UK Pounds
  • Shares Issued: 13.33m
  • Volume: 2,471
  • Market Cap: £13.33m
  • RiskGrade: 267

Feedback pleased with first-half progress

By Josh White

Date: Thursday 24 Jan 2019

LONDON (ShareCast) - (Sharecast News) - Specialist medical imaging technology company Feedback issued its unaudited half-year results for the six months ended 30 November on Thursday, reporting a 22% increase in invoiced sales year-on-year to £0.27m, due to new sales progress.
The AIM-traded firm said recognised revenue for the six-month period rose 4% to £0.24m, with its loss after tax for the six-month period widening to £0.37m from £0.35m, which the board put down to a higher cost base following its recruitment programme in 2018.

It saw increased investment in software development to £0.11m, from £0.04m, with its loss before interest, tax and amortisation for the half-year standing at £0.4m, from £0.34m.

Cash at 30 November stood at £1.367m, increasing from £0.267m, following Feedback's equity fundraise in November, which raised £1.375m before expenses.

On the operational front, Feedback Medical sales momentum continued to grow, with the firm reporting new 'TexRAD' sales into Czech Republic, Belgium, France, Italy, Portugal, India, the US and South Korea, during the first six months of the 2019 financial year.

It made new hires of a data scientist and product specialist for Cadran, with Feedback Medical signing an agreement in January with software development partner Future Processing as well.

That agreement would enhance Feedback Medical's software development capability and to distribute relevant Future Processing imaging analysis products.

The board said that would reinforce Feedback's software platform with improved clinical integration functionality, and provide access to specialist medical imaging software developers and AI specialists.

"We have seen positive progress across the business during this six-month period, building European sales as well as global sales in the US, South Korea and India," said Feedback executive chairman Dr Alastair Riddell.

"We have recruited to provide additional resource in data science and to support Cadran and this month, we have strengthened our partnership with Future Processing."

Dr Riddell said that would bring increased software development capabilities and improved functionality to Feedback's technology, as well as access to specialist medical imaging and AI expertise.

"Our fundraise in November positions us well to build on the operational progress already achieved and to continue to focus on our longer term goals of maximising the clinical opportunities for TexRAD and new business opportunities for Cadran."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Feedback Market Data

Currency UK Pounds
Share Price 100.00p
Change Today -2.50p
% Change -2.44 %
52 Week High 140.00
52 Week Low 58.00
Volume 2,471
Shares Issued 13.33m
Market Cap £13.33m
RiskGrade 267

Feedback Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
35.09% below the market average35.09% below the market average35.09% below the market average35.09% below the market average35.09% below the market average
9.68% above the sector average9.68% above the sector average9.68% above the sector average9.68% above the sector average9.68% above the sector average
Price Trend
11.93% below the market average11.93% below the market average11.93% below the market average11.93% below the market average11.93% below the market average
24.32% above the sector average24.32% above the sector average24.32% above the sector average24.32% above the sector average24.32% above the sector average
Income Not Available
Growth
50.64% above the market average50.64% above the market average50.64% above the market average50.64% above the market average50.64% above the market average
83.33% above the sector average83.33% above the sector average83.33% above the sector average83.33% above the sector average83.33% above the sector average

What The Brokers Say

Strong Buy 0
Buy 1
Neutral 0
Sell 0
Strong Sell 0
Total 1
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Feedback Dividends

No dividends found

Trades for --2024

Time Volume / Share Price
0 @ 0.000p

Feedback Key Personnel

CEO Tom Oakley
CFO Anesh Patel

Top of Page